haleon-1086h
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March
2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
Exhibit Number
|
Description
|
99.1
|
15
March 2024 - “Publication of Annual Report and Form 20-F
2023”
|
99.1
Haleon plc: Publication of Annual Report and Form 20-F
2023
15 March 2024: Haleon
plc (the "Company") has today published its Annual Report and Form
20-F for the year ended 31 December 2023 (the "Annual
Report").
The Annual Report has been submitted to the National Storage
Mechanism and will shortly be available for inspection
at data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Company will also file the Annual Report with the US Securities
and Exchange Commission today.
The Annual Report is publicly available on the Company's website
at www.haleon.com/investors/annual-report-2023.
In compliance with the Disclosure Guidance and Transparency Rules,
the Annual Report, as submitted to the National Storage Mechanism,
contains regulated information in unedited full text and is
available on the Company's website as noted above.
Shareholders may request a hard copy of the Annual Report,
including the complete audited financial statements of the Company.
Requests should be directed to: Company Secretariat, Haleon plc,
Building 5, First Floor, The Heights, Weybridge, KT13 0NY, United
Kingdom or to corporate.secretariat@haleon.com.
The Company's Annual General Meeting ("AGM") will take place on 8
May 2024. The Notice of AGM will be published and distributed to
shareholders in due course.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON PLC
(Registrant)
|
Date: March 15,
2024
|
By:
|
/s/
Amanda Mellor
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|